Significance of data analysis in the quality control of prenatal screening for Down syndrome

被引：7

作者：

Li, Yahong ^{[1
]}

Zhang, Xiaojuan ^{[1
]}

Hong, Dongyang ^{[1
]}

Guan, Xianwei ^{[1
]}

Lv, Shaolei ^{[2
]}

Sun, Yun ^{[1
]}

Jiang, Tao ^{[1
]}

机构：

[1] Nanjing Med Univ, Nanjing Matern & Child Hlth Care Hosp, Ctr Prenatal Diag, Affiliated Obstet & Gynecol Hosp, 123 Tianfei Rd, Nanjing 210004, Jiangsu, Peoples R China

[2] Zhejiang Biosan Biochem Technol Co Ltd, Hangzhou 310000, Zhejiang, Peoples R China

来源：

BIOMEDICAL REPORTS | 2018年 / 8卷 / 05期

基金：

中国国家自然科学基金;

关键词：

quality control; prenatal screening; Down syndrome;

D O I：

10.3892/br.2018.1078

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

Dual detection of alpha-fetoprotein (AFP) and free beta-human chorionic gonadotropin (beta-HCG) is a common screening method for Down syndrome in the second trimester and its efficacy is assessed by false-positive rate (FPR). The present study aimed to investigate the effects of the bias in median multiple of the median (mMoM) values of AFP and free beta-HCG on FPR. The bias in mMoM values of AFP and free beta-HCG and the bias in mMoM values under different gestational ages and weight groups were analyzed. Median equations were adjusted, and medians in LifeCycle software were replaced by local medians. Following two adjustments of the median equations, all indices including FPR, mMoM values of markers and mMoM values under different gestational ages and weight groups generally reached an ideal state. In conclusion, abnormal bias in mMoM values may prompt aberrant application of median equations, and regular monitoring of these indicators may be important for quality control in prenatal screening.

引用

页码：447 / 453

页数：7

共 50 条

[21] Fluorescence in situ hybridization of chorionic interphase cells for prenatal screening of Down syndrome
Tóth, A
Tardy, EP
Hajdu, K
Bátorfi, J
Doszpod, J
Egyed, J
Gáti, I
EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 2001, 94 (01) : 46 - 50
[22] Quality assessment in prospective nuchal translucency screening for Down syndrome
Wojdemann, KR
Christiansen, M
Sundberg, K
Larsen, SO
Shalmi, A
Tabor, A
ULTRASOUND IN OBSTETRICS & GYNECOLOGY, 2001, 18 (06) : 641 - 644
[23] Application of droplet digital PCR for prenatal screening of Down syndrome
Wu, Manwu
Yang, Zhihao
Yu, Xinzhong
Qian, Feiyan
Qian, Lei
Li, Wei
CLINICAL AND EXPERIMENTAL OBSTETRICS & GYNECOLOGY, 2018, 45 (02) : 231 - 236
[24] Down Syndrome in India-Diagnosis, Screening, and Prenatal Diagnosis
Verma, Ishwar C.
Lall, Meena
Puri, Ratna Dua
CLINICS IN LABORATORY MEDICINE, 2012, 32 (02) : 231 - +
[25] Evolution of Down Syndrome Prenatal Screening Clinical Practices in Quebec
Gareau-Leonard, Audree
Fillion, Alexandre
Labine, Laurence
Gasse, Cedric
Demers, Suzanne
Bujold, Emmanuel
JOURNAL OF OBSTETRICS AND GYNAECOLOGY CANADA, 2020, 42 (04) : 439 - 445
[26] Prenatal screening, ethics and Down's syndrome: A literature review
Alderson, P
NURSING ETHICS, 2001, 8 (04) : 360 - 374
[27] Assessment of the value of reporting partial screening results in prenatal screening for Down syndrome
Hackshaw, AK
Wald, NJ
PRENATAL DIAGNOSIS, 2001, 21 (09) : 737 - 740
[28] Prenatal Testing for Down Syndrome: The Perspectives of Parents of Individuals With Down Syndrome
Inglis, Angela
Hippman, Catriona
Austin, Jehannine C.
AMERICAN JOURNAL OF MEDICAL GENETICS PART A, 2012, 158A (04) : 743 - 750
[29] On screening for Down syndrome
van Lith, JMM
Gynaecology, Obstetrics, and Reproductive Medicine in Daily Practice, 2005, 1279 : 221 - 224
[30] Prenatal screening for Down syndrome in England and Wales and population-based birth outcomes
Smith-Bindman, R
Chu, P
Bacchetti, P
Waters, JJ
Mutton, D
Alberman, E
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2003, 189 (04) : 980 - 985

← 1 2 3 4 5 →